CD25, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD25, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD25, Human |
| Clone | REA945 |
| Host Species | Recombinant Human |
| Reactive Species | human, nonhuman primate |
| Isotype | IgG1 |
| Format | Vio Bright V423 conjugate |
| Size | 100 tests in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD25 Antibody, anti-human, Vio® Bright V423, REAfinity™. Clone REA945 recognizes the human CD25 antigen, a 28 kDa glycoprotein also known as the low-affinity interleukin-2 receptor alpha chain (IL-2Rα). CD25 is expressed on activated T and B cells, on macrophages, and on a subset of non-activated CD4+ regulatory T cells. CD25 plays an essential role in the regulation of immune tolerance by controlling regulatory T cells activity. The CD25 antigen contains three epitope regions called A, B, and C. Clone REA945 recognizes epitope region B. | Additional information: Clone REA945 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | IL2RA, IDDM10, IL2R, TCGFR, p55, Tac, IL-2Rα |
| Gene, Accession # | Gene ID: 3559 |
| Catalog # | 130-126-613 |
| Price | $455 |
| Order / More Info | CD25, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Sakaguchi, S. et al. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164. | Shevach, E. M. (2001) Certified professionals: CD4+CD25+ suppressor T cells. J. Exp. Med. 193 (11): F41-F46. | Maloy, K. J. et al. (2001) Regulatory T cells in the control of immune pathology. Nat Immunol 2 (9): 816-822. | Lamprecht, B. et al. (2008) Aberrant expression of the T?2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112 (8): 3339-3347. | Chaput, N. et al. (2013) Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome. Oncoimmunology 2 (2): e23080. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies